MIRM 39.32 Mirum Pharmaceuticals, Inc.
| Range: | 23.14-45.23 | Vol Avg: | 509315 | Last Div: | 0 | Changes: | 1.63 |
| Beta: | 1.14 | Cap: | 1.91B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jul 18 2019 | Empoloyees: | 294 | ||
| CUSIP: | 604749101 | CIK: | 0001759425 | ISIN: | US6047491013 | Country: | US |
| CEO: | Mr. Christopher Peetz | Website: | https://www.mirumpharma.com | ||||
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow